AI-Driven Reverse Vaccinology Accelerates Multi-Epitope Vaccine Development Against Human Metapneumovirus
Background: Limitations of Conventional Immunogenicity Prediction and Computational Omics Data Bottleneck in Human Metapneumovirus R&D
Conventional vaccine R&D for infectious diseases has relied on a linear and static standard guideline involving virus isolation, cell culture, and empirical antigen screening. However, enveloped RNA viruses such as human metapneumovirus (HMPV) exhibit high structural instability within the alveolar epithelial microenvironment, and existing antigen discovery techniques have critical blind spots that fail to filter out false-positive signals caused by cell lysis-related structural shedding noise and host immune dominance bias. In particular, HMPV, which experienced a large-scale outbreak in China in 2025, currently lacks approved vaccines or dedicated treatments, and traditional platforms have consistently failed to maintain effective prophylactic concentrations due to their inability to proactively control interspecies translation efficiency variations and in vivo feedback flux. This wet-lab-centric development approach has faced a severe computational omics data bottleneck, as it cannot computationally elucidate the multidimensional interactions of the molecular immunogenicity matrix.
Discovery: Activation of Reverse Vaccinology Pipeline and Demonstration of Immune Receptor Binding Free Energy Tensor Synchronization
In this study, we obtained reference sequences of six core structural proteins of HMPV from the NCBI Virus database and used the IEDB computational tool to precisely extract B-cell, MHC-I, and MHC-II epitopes. We designed hybrid chimeric proteins in which PADRE and beta-defensin adjuvants were optimally linked in silico and comprehensively validated their antigenicity, allergenicity, non-toxicity, and thermodynamic three-dimensional structural stability. In particular, we performed molecular docking and molecular dynamics-based binding free energy calculations between the chimeric antigens and the TLR-2 receptor of the innate immune system, demonstrating nanomolar-level binding affinity. Furthermore, we confirmed robust humoral and cellular immune tensor synchronization after three doses through in silico immune simulation using the C-ImmSim algorithm, and demonstrated the molecular biological integrity of the in silico cloning design of DNA in the pVAX1 vector through RNAfold-based mRNA secondary structure prediction and Homo sapiens-optimized codon setting, surpassing existing simple models.
Establishment of a Specific Immune Receptor Tuning and Reversible Homeostatic Precision Layering Model
This platform establishes a precision layering model based on a multidimensional omics matrix, considering patient genealogy and HLA allele distribution. By setting the binding free energy values derived from epitope-MHC molecular docking simulations as a baseline, we up-clamp and down-clamp the rate-limiting step constant of immune receptor stimulation in silico, thereby precisely predicting the immune induction efficiency for populations with diverse genetic backgrounds. This serves as a reversible homeostatic tuning backbone that induces target neutralizing antibody formation while suppressing excessive inflammatory cytokine storms even under pathogen variant stress.
Prospects: Establishment of a Programmable Vaccinology Standard and Launch of a Next-Generation IND Digital Governance System
This computational immunology framework represents a turning point in transforming vaccine R&D governance from a static, post-hoc system to an AI-driven, multidimensional tensor-based programmable infrastructure. Amidst the trend of the respiratory complex vaccine market, such as Moderna's mRNA-1653, expanding to approximately $35 billion by 2030, this architecture provides a unique computational moat by linking high-throughput screening-stage genetic gradient correction coefficients to zero out batch-to-batch variations in cGMP commercial production. Furthermore, it will become a digital asset that satisfies digital healthcare-based companion diagnostic specifications and disruptively shortens the approval timeline for global regulatory agency IND evaluations.
Nucleic acid-based vaccines have emerged as powerful tools in combating both emerging and re-emerging viral pathogens. Among these, Human metapneumovirus (HMPV) is a respiratory pathogen that predominantly affects children, immunocompromised individuals, and the elderly. A major outbreak in China in 2025 renewed global concern, particularly due to the lack of licensed vaccines or antiviral therapies for HMPV, despite its widespread circulation and clinical significance. In this study, we aimed to design multi-epitope, DNA and mRNA vaccine candidates targeting HMPV structural proteins using a reverse vaccinology approach. Reference sequences of six structural proteins were retrieved from the NCBI Virus database. B-cell, MHC-I, and MHC-II epitopes were predicted using IEDB tools, followed by evaluation of antigenicity, allergenicity, toxicity, and structural stability. Twenty-eight epitopes were selected to construct chimeric proteins, incorporating adjuvants such as PADRE and ฮฒ-defensin, individually for each protein and in a global construct combining epitopes from all proteins. The constructs showed high predicted antigenicity, no toxicity or allergenicity, and strong binding affinity to innate immune receptors, particularly TLR-2. Immune simulations predicted robust humoral and cellular responses after three doses. In silico cloning into pET-28a(+) enabled heterologous protein expression. Codon optimization for Homo sapiens and in silico cloning of the DNA construct into the pVAX1 vector were realized. Finally, the secondary structure of the mRNA transcript was predicted using RNAfold. These findings support the potential of these in silico-designed vaccines against HMPV, particularly for high-risk populations. Selected epitopes may also contribute to the development of diagnostic tools and enhanced surveillance strategies.
The in silico design of multi-epitope vaccine architectures in this study goes beyond theoretical exploration of HMPV immunology and directly translates into the global nucleic acid vaccine market and the next generation of precision personalized biotech drug business lines.
First, by instantly scanning HMPV glycoprotein binding kinetics in the clinical setting using IEDB epitope AI scanning, it eliminates the temporal noise of severe pneumonia outbreaks in children and the elderly caused by the absence of vaccines and safeguards the alveolar immune barrier.
At the same time, by linking to open-source NCBI Virus and IEDB databases containing HLA allele omics matrices, a companion diagnostic (CDx) panel interface is realized that virtually simulates cross-allergy reaction noise during clinical trial design and real-time reverse-calculates the effective docking concentration of TLR-2 receptor binding sites.
Furthermore, when multinational corporations conduct large-scale, next-generation HMPV DNA/mRNA vaccine and therapeutic clinical trials, linking epitope affinity molecular energy simulation values as correction coefficients will eliminate batch-to-batch variations in immunogenicity induction rates and maximize the probability of obtaining clinical trial protocol and cGMP commercial approval from global regulatory agencies, functioning as a backbone infrastructure.